What is ctDNA testing and should Hairy Cell Leukemia patients get it

ctDNA Testing and Hairy Cell Leukemia: What You Should Know

What is ctDNA Testing?

ctDNA stands for circulating tumor DNA. This is a blood test that detects tiny fragments of cancer cell DNA floating in your bloodstream. Think of it as a "liquid biopsy" — instead of taking a tissue sample, doctors analyze cancer DNA circulating in your blood.

Here's how it works:

• Cancer cells naturally shed DNA into the bloodstream as they die and break down
• A blood sample is drawn and analyzed in a lab using sensitive molecular techniques
• The test can detect cancer-related genetic changes (mutations) at very low levels
• Results can show whether cancer cells are present, even when other tests appear normal

ctDNA and Hairy Cell Leukemia: Current Evidence

Based on the NCCN Guidelines for Hairy Cell Leukemia (Version 1.2026), here's what's important to know:

What the Guidelines Emphasize Instead

The NCCN Guidelines focus on minimal residual disease (MRD) assessment using different methods:

• Bone marrow examination is the standard way to evaluate response to treatment
• Immunohistochemistry (IHC) — looking at cells under a microscope with special stains
• Flow cytometry — using fluorescent markers to identify cancer cells
• Morphologic assessment — examining the appearance of cells in bone marrow and blood

The guidelines specifically note that MRD testing helps stratify patients based on whether they achieve complete response (CR) with or without detectable MRD.

Why This Matters for HCL Patients

According to NCCN Guidelines, response assessment in hairy cell leukemia is defined by:

• Complete Response (CR): Near-normal blood counts, no hairy cells visible on bone marrow exam, and absence of disease on microscopic examination
• MRD status: Whether minimal disease remains detectable after treatment

Should HCL Patients Get ctDNA Testing?

The honest answer: This is not yet standard practice for hairy cell leukemia, based on current NCCN Guidelines.

Here's why:

1. Different disease biology: Hairy cell leukemia is a rare B-cell leukemia with specific characteristics (BRAF V600E mutation in ~95% of cases). The standard monitoring tools (bone marrow biopsy, flow cytometry, morphology) are well-established and effective.

2. Proven monitoring methods exist: The NCCN Guidelines recommend bone marrow examination and immunophenotyping as the essential tools for assessing treatment response — these have decades of clinical experience.

3. Emerging research: While ctDNA testing shows promise in other blood cancers, its specific role in HCL monitoring is still being researched and is not yet incorporated into standard NCCN recommendations.

Questions to Ask Your Oncologist

If you're interested in ctDNA testing or advanced monitoring:

1. "Are there clinical trials using ctDNA testing for hairy cell leukemia that I might be eligible for?"

2. "What is my current MRD status based on my bone marrow biopsy and flow cytometry results?"

3. "How will you monitor my response to treatment, and what tests will you use?"

4. "If my standard tests show complete response, do you recommend any additional monitoring with newer blood tests?"

5. "Are there any research studies at this institution exploring new monitoring methods for HCL?"

The Bottom Line

For hairy cell leukemia patients, bone marrow biopsy with immunophenotyping and morphologic assessment remain the standard of care for monitoring treatment response, according to NCCN Guidelines. While ctDNA testing is an exciting development in cancer care, it's not yet standard for HCL.

However, this is an evolving field. If your doctor suggests ctDNA testing as part of a clinical trial or research study, that could be worth discussing — especially if you're interested in participating in cutting-edge research.

Your oncologist can best determine whether additional monitoring tools beyond standard bone marrow assessment would be beneficial for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.